Etanercept as a salvage treatment for refractory aplastic anemia

Carlo Dufour, Raffaella Giacchino, Pietro Ghezzi, Rossella Tonelli, Elisa Ferretti, A. Pitto, Vito Pistoia, Tiziana Lanza, Johanna Svahn

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

About 10-15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.

Original languageEnglish
Pages (from-to)522-525
Number of pages4
JournalPediatric Blood and Cancer
Volume52
Issue number4
DOIs
Publication statusPublished - Apr 2009

Fingerprint

Refractory Anemia
Salvage Therapy
Platelet Transfusion
Aplastic Anemia
Immunosuppression
Iron Overload
Hematopoietic Stem Cell Transplantation
Transaminases
Liver
Therapeutics
Infection
Etanercept

Keywords

  • Anti-TNF
  • Complicated aplastic anemia
  • HCV infection

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Medicine(all)

Cite this

Etanercept as a salvage treatment for refractory aplastic anemia. / Dufour, Carlo; Giacchino, Raffaella; Ghezzi, Pietro; Tonelli, Rossella; Ferretti, Elisa; Pitto, A.; Pistoia, Vito; Lanza, Tiziana; Svahn, Johanna.

In: Pediatric Blood and Cancer, Vol. 52, No. 4, 04.2009, p. 522-525.

Research output: Contribution to journalArticle

Dufour C, Giacchino R, Ghezzi P, Tonelli R, Ferretti E, Pitto A et al. Etanercept as a salvage treatment for refractory aplastic anemia. Pediatric Blood and Cancer. 2009 Apr;52(4):522-525. https://doi.org/10.1002/pbc.21886
Dufour, Carlo ; Giacchino, Raffaella ; Ghezzi, Pietro ; Tonelli, Rossella ; Ferretti, Elisa ; Pitto, A. ; Pistoia, Vito ; Lanza, Tiziana ; Svahn, Johanna. / Etanercept as a salvage treatment for refractory aplastic anemia. In: Pediatric Blood and Cancer. 2009 ; Vol. 52, No. 4. pp. 522-525.
@article{a566d052f4d040d5ba9a8bd4680da16c,
title = "Etanercept as a salvage treatment for refractory aplastic anemia",
abstract = "About 10-15{\%} of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.",
keywords = "Anti-TNF, Complicated aplastic anemia, HCV infection",
author = "Carlo Dufour and Raffaella Giacchino and Pietro Ghezzi and Rossella Tonelli and Elisa Ferretti and A. Pitto and Vito Pistoia and Tiziana Lanza and Johanna Svahn",
year = "2009",
month = "4",
doi = "10.1002/pbc.21886",
language = "English",
volume = "52",
pages = "522--525",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Etanercept as a salvage treatment for refractory aplastic anemia

AU - Dufour, Carlo

AU - Giacchino, Raffaella

AU - Ghezzi, Pietro

AU - Tonelli, Rossella

AU - Ferretti, Elisa

AU - Pitto, A.

AU - Pistoia, Vito

AU - Lanza, Tiziana

AU - Svahn, Johanna

PY - 2009/4

Y1 - 2009/4

N2 - About 10-15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.

AB - About 10-15% of patients with acquired aplastic anemia (AAA) have resistant/recurrent disease not eligible for standard treatment like hematopoietic stem cell transplantation and/or combined immunosuppression. We report a 17-year-old male with an 11 years history of AAA who, after two courses of immunosuppression, was red cell transfusion-dependent, severely thrombocytopenic, refractory to platelet transfusion, had iron overload and post-transfusion HCV infection. This patient achieved transfusion independence from platelets and normalized Hb after treatment with the anti-TNF agent Etanercept. Over a 12 months follow-up he experienced only transient increase of liver transaminases.

KW - Anti-TNF

KW - Complicated aplastic anemia

KW - HCV infection

UR - http://www.scopus.com/inward/record.url?scp=62449291872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62449291872&partnerID=8YFLogxK

U2 - 10.1002/pbc.21886

DO - 10.1002/pbc.21886

M3 - Article

VL - 52

SP - 522

EP - 525

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -